Daurismo Background
Daurismo Background

DAURISMO is the first and only hedgehog pathway inhibitor in the treatment of AML

document icon

Read the full press release about
the FDA approval of DAURISMO

Full Prescribing Information,
including BOXED WARNING
and Medication Guide

AML=acute myeloid leukemia; LDAC=low-dose cytarabine.